The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a UK-wide consultation on proposals that would allow schools to purchase and hold spare adrenaline nasal sprays for emergency use in children…
Read more
The UK’s first needle-free adrenaline nasal spray, EURneffy® 1mg, is now available on prescription for younger children at risk of serious allergic reactions. The newly available 1 mg dose is licensed for…
Read more
Photo credit: Mast cells – Zoe Whyte, Mast cells, used with permission Mast cell diseases can go unnoticed by almost everyone, yet be unmistakable to the person living with one. Today, on…
Read more
An immunotherapy treatment for house dust mite allergy has been made available through the NHS in Scotland. The Scottish Medicines Consortium (SMC) has accepted Acarizax (12 SQ-HDM sublingual immunotherapy) for adults aged 18–65 with moderate…
Read more
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a lower-dose version of the adrenaline nasal spray, EURneffy®, for the emergency treatment of serious allergic reactions (anaphylaxis) in children aged four…
Read more
The National Institute for Health and Care Excellence (NICE) has published updated guidance on the assessment and referral of people following emergency treatment for anaphylaxis. This new guideline replaces NICE guideline CG134…
Read more
New research from the University of Bristol and Bristol Royal Hospital for Children has highlighted critical delays in the use of adrenaline auto-injectors (AAIs) in children experiencing fatal food-induced anaphylaxis, prompting calls for urgent…
Read more
Allergies can impact almost every aspect of daily life — from school and travel to attending a hospital appointment. That is why Anaphylaxis UK advocates for a safer, allergy-aware approach across all…
Read more
A recent study published in The Journal of Allergy and Clinical Immunology: In Practice looked at popular allergy-related posts on TikTok, Instagram, Facebook and X to see what kind of misinformation is being shared and how people respond to…
Read more